Alnylam Pharmaceuticals faces near-term headwinds from TTR franchise momentum concerns. Click here to read why ALNY stock is ...
BridgeBio Oncology Therapeutics (BBOT) targets KRAS and PI3Ka malignancies with next-generation small molecule therapeutics, ...
Quarterly beat puts the spotlight on Attruby BridgeBio Pharma (BBIO) just delivered quarterly revenue that topped expectations, powered by stronger than anticipated U.S. sales of its cardiomyopathy ...
Fintel reports that on December 11, 2025, Bernstein initiated coverage of BridgeBio Pharma (NasdaqGS:BBIO) with a Outperform ...
Bernstein analyst William Pickering initiated coverage on BridgeBio Pharma Inc (NASDAQ: BBIO) with an Outperform rating and announced a price target of $94. BridgeBio Pharma shares closed at $72.70 on ...
TipRanks on MSN
BridgeBio initiated with an outperform at Bernstein
Bernstein initiated coverage of BridgeBio (BBIO) with an Outperform rating and $94 price target The firm believes expectations for Attruby are ...
BridgeBio Pharma (BBIO) has surged 145% over the past year, reaching an all-time high of $75.10. BBIO maintains a strong ...
Prognostications that the AI bubble is grossly overbought have been increasing. The fact that the Magnificent 7 AI stocks, ...
Detailed price information for Bridgebio Pharma Inc (BBIO-Q) from The Globe and Mail including charting and trades.
Detailed price information for Bridgebio Pharma Inc (BBIO-Q) from The Globe and Mail including charting and trades.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback